Shares of Ibere Pharmaceuticals (NYSE:IBER – Get Rating) rose 0.1% during trading on Wednesday . The company traded as high as $9.93 and last traded at $9.92. Approximately 13,414 shares traded hands during trading, a decline of 72% from the average daily volume of 47,352 shares. The stock had previously closed at $9.91.
Ibere Pharmaceuticals Stock Performance
The business’s 50 day moving average is $9.87 and its 200 day moving average is $9.82.
Institutional Investors Weigh In On Ibere Pharmaceuticals
Hedge funds have recently made changes to their positions in the business. Omni Event Management Ltd increased its holdings in Ibere Pharmaceuticals by 9.5% in the first quarter. Omni Event Management Ltd now owns 422,029 shares of the company’s stock valued at $4,140,000 after buying an additional 36,789 shares in the last quarter. Saba Capital Management L.P. acquired a new stake in Ibere Pharmaceuticals during the first quarter worth approximately $785,000. Finally, Bank of America Corp DE acquired a new stake in Ibere Pharmaceuticals during the first quarter worth approximately $3,139,000. Institutional investors and hedge funds own 71.43% of the company’s stock.
About Ibere Pharmaceuticals
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
- Get a free copy of the StockNews.com research report on Ibere Pharmaceuticals (IBER)
- 2 Semiconductor Stocks To Watch For Reversals
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
Receive News & Ratings for Ibere Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ibere Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.